Analyst Ratings for Ascendis Pharma (ASND)
ASND Rating Summary
ASND Price Target Summary
- Highest: $360.00 (Citi)
- Lowest: $39.00 (BMO Capital)
- Average: $294.35
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$294.35 (+13.1%)
* Over Last 12-Mos
Rating Score: 9.6 / 10
Percentile Rank: 91%
Rating Score: 9.6 / 10
Percentile Rank: 91%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/27/2026 | H.C. Wainwright » Updated 8/31/2026 |
Mitchell S. Kapoor | New Coverage | Buy (N/A) |
345.00 (N/A) |
250.25 (260.25) |
4% | Details |
| 8/18/2026 | BMO Capital | David Lebowitz | New Coverage | Outperform (N/A) |
39.00 (N/A) |
247.40 (260.25) |
5.19% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
